An 8-week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension.

Trial Profile

An 8-week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 May 2017

At a glance

  • Drugs Aliskiren (Primary) ; Hydrochlorothiazide
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 09 Jun 2011 Pooled pharmacodynamic analysis results assessing the effect of treatment on plasma renin activity published in the Journal of Clinical Pharmacology.
    • 09 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top